Creative Medical Technology Holdings, Inc. CELZ 深 沪

Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms

Creative Medical received a U.S. patent allowance for its MyeloCelz™ exosome technology, designed to suppress autoimmune destruction of insulin-producing cells in Type 1 diabetes. This cell-free platform promotes antigen-specific immune tolerance, complementing the company's existing diabetes therapies like CELZ-101 and CELZ-201. The patent strengthens Creative Medical's intellectual property portfolio, supporting its multi-faceted approach to di...

08-06 13:15

Why Constellation Brands Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Shares of Constellation Brands Inc (NYSE:STZ) rose sharply in pre-market trading after the company reported upbeat first-quarter financial results and raised its FY27 earnings guidance. Constellation Brands reported quarterly earnings of $3.43 per share, which beat the consensus estimate of $3.21 by...

07-01 17:10

Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds

Creative Medical Technology Holdings, Inc. (CELZ) has entered into agreements with certain warrant holders to exercise outstanding warrants to purchase up to 2,790,340 shares at a reduced price of $1.60 per share, generating approximately $4.5 million in gross proceeds. In exchange, the company will issue new warrants for up to 5,580,680 shares, exercisable at $1.60 per share, contingent on shareholder approval. The transaction is expected to clo...

06-30 18:07

Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain

Creative Medical Technology Holdings, Inc. announced FDA clearance for an expansion of its ADAPT clinical trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain. The expansion will enroll 15 additional patients with moderate opioid use (less than 90 mg morphine equivalents daily) to further assess safety and efficacy. Enrollment is already over 85% complete, leveraging the company's AI-driven pain monitoring system. Positive interim d...

06-22 13:15

Creative Medical Tech Q1 EPS $(0.38) Beats $(0.39) Estimate

Creative Medical Tech (NASDAQ:CELZ) reported quarterly losses of $(0.38) per share which beat the analyst consensus estimate of $(0.39) by 2.56 percent. This is a 54.22 percent increase over losses of $(0.83) per share

05-09 06:12

Pacira BioSciences Q1 2026 Earnings Call Transcript

On Thursday, Pacira BioSciences (NASDAQ:PCRX) discussed first-quarter financial...

05-01 05:27

Creative Medical Technology Announces Results From Pilot Study Of Ultrasome, Proprietary Cell-Free Regenerative Therapy For Treatment Of Osteoarthritis Of Knee

Ultrasome™ Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis MarketPHOENIX, April 28, 2026 (GLOBE NEWSWIRE) -- Creative Medical

04-28 21:04

Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies

04-28 13:01

Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline

Creative Medical Technology Holdings Inc. (CELZ) has achieved its second INN milestone with the WHO, with "etaroleucel" proposed for CELZ-101, its autologous Treg immunotherapy program. This builds on the prior INN approval of "olastrocel" for CELZ-201, highlighting the company's ability to advance multiple cell therapy programs. The milestones underscore regulatory progress and global credibility, supporting future clinical development and comme...

02-10 14:00

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers INVO Fertility (NASDAQ:IVF) shares increased by 345.6% to $3.62 during...

01-20 20:05